(VIANEWS) – KBC ANCORA (KBCA.BR), GJENSIDIGE FORSIKR (GJF.OL), DOCK.PETR.AMBES AM (DPAM.PA) are the highest payout ratio stocks on this list.
We have collected information about stocks with the highest payout ratio up until now. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. KBC ANCORA (KBCA.BR)
85.39% Payout Ratio
KBC Ancora SCA holds participating interest in KBC Group SA. The company was formerly known as Almancora SCA and changed its name to KBC Ancora SCA in June 2007. KBC Ancora SCA was incorporated in 1998 and is based in Leuven, Belgium. KBC Ancora SCA is a subsidiary of Cera SC.
Earnings Per Share
As for profitability, KBC ANCORA has a trailing twelve months EPS of €-0.21.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.98%.
Volume
Today’s last reported volume for KBC ANCORA is 23016 which is 57.79% below its average volume of 54539.
Yearly Top and Bottom Value
KBC ANCORA’s stock is valued at €42.68 at 22:10 EST, way under its 52-week high of €49.88 and way higher than its 52-week low of €31.66.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 7, 2022, the estimated forward annual dividend rate is 8.99 and the estimated forward annual dividend yield is 21.13%.
More news about KBC ANCORA.
2. GJENSIDIGE FORSIKR (GJF.OL)
85.18% Payout Ratio
Gjensidige Forsikring ASA provides general insurance and pension products in Norway, Sweden, Denmark, Latvia, Lithuania, and Estonia. The company operates through six segments: General Insurance Private, General Insurance Commercial, General Insurance Denmark, General Insurance Sweden, General Insurance Baltics, and Pension. It offers motor, accident and health, travel, leisure craft, valuables, liability, commercial, marine/transport, agriculture, natural perils, life, and pet insurance products. The company also provides defined contribution occupational pension schemes for businesses, which include disability pension, spouse/cohabitant pension, and child's pension products. It distributes its products through various distribution channels comprising office channel, call center, Internet, partners, and brokers to private and commercial customers. The company was founded in 1816 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, GJENSIDIGE FORSIKR has a trailing twelve months EPS of kr13.55.
PE Ratio
GJENSIDIGE FORSIKR has a trailing twelve months price to earnings ratio of 12.72. Meaning, the purchaser of the share is investing kr12.72 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.89%.
More news about GJENSIDIGE FORSIKR.
3. DOCK.PETR.AMBES AM (DPAM.PA)
79.21% Payout Ratio
Les Docks des Pétroles d'Ambès -SA engages in the storage and shipping of petroleum products in France. It stores and distributes species, diesel, and combustibles, as well as bio, jet, technical, and marine fuel products. The company was founded in 1930 and is based in Carbon-Blanc, France.
Earnings Per Share
As for profitability, DOCK.PETR.AMBES AM has a trailing twelve months EPS of €33.21.
PE Ratio
DOCK.PETR.AMBES AM has a trailing twelve months price to earnings ratio of 14.27. Meaning, the purchaser of the share is investing €14.27 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.95%.
Yearly Top and Bottom Value
DOCK.PETR.AMBES AM’s stock is valued at €474.00 at 22:10 EST, under its 52-week high of €496.00 and way above its 52-week low of €426.00.
More news about DOCK.PETR.AMBES AM.
4. UCB (UCB.BR)
60.47% Payout Ratio
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €3.77.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 22.82. Meaning, the purchaser of the share is investing €22.82 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.81%.
Moving Average
UCB’s value is higher than its 50-day moving average of €78.64 and way above its 200-day moving average of €75.98.
More news about UCB.
5. BETER BED (BBED.AS)
40.54% Payout Ratio
Beter Bed Holding N.V. retails and wholesales bedroom furnishing products in the Netherlands and Belgium. The company offers beds, box springs, mattresses, bed bases, and bed textiles, as well as home delivery services. It operates retail stores under the Beter Bed and Beddenreus brand names. The company also markets its products under the Bright, Beter Bed Basic, Element, Kårlsson, M-concept, M line, Topcare, Wave, and Leazzzy brands, as well as through online platforms. Beter Bed Holding N.V. was founded in 1981 and is headquartered in Uden, the Netherlands.
Earnings Per Share
As for profitability, BETER BED has a trailing twelve months EPS of €0.31.
PE Ratio
BETER BED has a trailing twelve months price to earnings ratio of 10.1. Meaning, the purchaser of the share is investing €10.1 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16%.
Sales Growth
BETER BED’s sales growth for the current quarter is 0.7%.
More news about BETER BED.
6. BOIRON (BOI.PA)
32.87% Payout Ratio
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €1.5.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 25.78. Meaning, the purchaser of the share is investing €25.78 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.
More news about BOIRON.
